A Prospective, Multi-Institutional Assessment of Four Assays for PD-L1 Expression in NSCLC by Immunohistochemistry

IMPORTANCE: Four assays have been registered with the FDA to detect PD-L1 to enrich for patient response to anti-PD-1/PD-L1 therapies. The tests use four separate PD-L1 antibodies on two separate staining platforms and have their own scoring systems which raises questions about their similarity and...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Oncol
Hlavní autoři: Rimm, David L., Han, Gang, Taube, Janis M., Yi, Eunhee S., Bridge, Julia A., Flieder, Douglas B., Homer, Robert, West, William W., Wu, Hong, Roden, Anja C., Fujimoto, Junya, Yu, Hui, Anders, Robert, Kowalewski, Ashley, Rivard, Christopher, Rehman, Jamaal, Batenchuk, Cory, Burns, Virginia, Hirsch, Fred R., Wistuba, Ignacio I.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5650234/
https://ncbi.nlm.nih.gov/pubmed/28278348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.0013
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky